A new version of the Sputnik V vaccine has been developed in Russia to combat the Delta and Omicron strains

The Gamaleya National Research Center for Epidemiology and Microbiology has developed a new

a version of the Sputnik V vaccine to combat the Delta and Omicron strains of coronavirus.The efficacy of the drug has been proven.

This is evidenced by tests:during the experiments, the vaccine showed a significant decrease in the viral load on the lungs in animals infected with the BA5 omicron strain of coronavirus. The new version of the drug takes into account the L-452-R mutation, which is present in the BA5 variant but not in the BA1 variant.

The center of Gamaleya is confident that their development will achieve high results in preventing the incidence of COVID-19.

In addition, already developed vaccine optionsSputnik V showed high efficiency against hospitalizations from Omicron - 97% and 99.4% against critical cases when boosted with Sputnik Light or revaccinated with Sputnik V.